Molecular classification of hormone receptor-positive /HER2-positive breast cancer reveals potential neoadjuvant therapeutic strategies
Abstract Significant heterogeneity exists in hormone receptor (HR)-positive/HER2-positive (HR+/HER2+) breast cancer, contributing to suboptimal pathological complete response rates with conventional neoadjuvant treatment regimens. Overcoming this challenge requires precise molecular classification,...
Saved in:
| Main Authors: | Chao Liu, Lisha Sun, Nan Niu, Pengjie Hou, Guanglei Chen, Hao Wang, Zhan Zhang, Xiaofan Jiang, Qianshi Xu, Yafei Zhao, Yimin Wang, Yuan Shi, Mingxin Liu, Yongliang Yang, Wei Qian, Jiandong Wang, Caigang Liu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2025-03-01
|
| Series: | Signal Transduction and Targeted Therapy |
| Online Access: | https://doi.org/10.1038/s41392-025-02181-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot study
by: Yu Zhang, et al.
Published: (2025-07-01) -
Neoadjuvant ARX788 plus pyrotinib versus trastuzumab, pertuzumab, docetaxel and carboplatin for HER2-positive breast cancer: a randomised phase 2b trial
by: Nan Niu, et al.
Published: (2025-07-01) -
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
by: Fei Xing, et al.
Published: (2023-01-01) -
Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy
by: Luca Mastrantoni, et al.
Published: (2025-02-01) -
Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy
by: Sonia Pernas, et al.
Published: (2024-11-01)